Tracers / [177Lu]Lu-OxFol-1
[177Lu]Lu-OxFol-1
Also written as [Lu-177]Lu-OxFol-1
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- folic acid-based albumin-binding radioconjugate targeting folate receptor
- Target / mechanism
- Folate receptor (FR) targeting PMID 33063250
- Clinical application
- Folate receptor-targeted radionuclide therapy of FR-positive tumors PMID 33063250
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | >99% | OxFol-1 (cm10) | 33063250 2021 Eur J Nucl Med Mol Imaging The radiolabeling of the folate conjugates with lutetium-177 ... was performed at pH ~ 4.5 using no-carrier-added lutetium-177 |
Need this precursor?We can point you to suppliers for [177Lu]Lu-OxFol-1, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 33063250. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.